DoD tests AI models that make it easy to switch from vendors like Palantir
CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company with a market capitalization of $2.6 million and current share price of $0.94, announced today its participation at Digestive Disease Week (DDW) 2025, scheduled for May 3-6, where it will present data from its lead program PALI-2108, a colon-specific PDE4 inhibitor prodrug for the treatment of ulcerative colitis. According to InvestingPro analysis, the company currently trades below its Fair Value, with analysts setting price targets ranging from $8 to $38.
The company’s abstract on PALI-2108 has been recognized in the top 10% of all abstracts for poster presentation at the conference. The data will be showcased in two sessions, with the first on May 4, focusing on the bioinformatic approach to PALI-2108 treatment in ulcerative colitis, which suggests potential anti-fibrotic efficacy. The second session, on May 5, will present findings on how PALI-2108 is bioactivated in the colon and reduces colon tissue PDE4B in a dose-dependent manner, leading to increased c-AMP and suppressed TNF-α in a mouse model of colitis.
DDW is a premier event that convenes experts in gastroenterology to discuss the latest advancements in digestive diseases. Palisade Bio’s inclusion in this event underscores the significance of their research in the field.
Palisade Bio is dedicated to developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, with the belief that targeted approaches can transform treatment landscapes. While InvestingPro data shows the company maintains more cash than debt on its balance sheet, it’s also quickly burning through available funds. Despite the company’s forward-looking statements regarding the efficacy and potential of PALI-2108, it acknowledges that the drug is still in the early stages of clinical development and may face risks and uncertainties, including the need for further funding and regulatory approval. Get access to 12 more exclusive InvestingPro Tips and comprehensive financial metrics to make informed investment decisions.
Investors and industry watchers are advised that the company’s actual results and timing of events could differ materially from those anticipated in such forward-looking statements due to a variety of risks and uncertainties detailed in the company’s SEC filings. The stock has shown recent momentum with a 14% gain over the past week, though long-term performance remains challenging. Interested investors should note that Palisade Bio’s next earnings report is scheduled for March 27, 2025.
The information presented in this article is based on a press release statement from Palisade Bio, Inc.
In other recent news, Palisade Bio has received 1.39 million Canadian dollars in Scientific Research and Experimental Development tax credits from Canada. This funding will reimburse the company for pre-clinical costs related to PALI-2108, a drug developed in collaboration with Giiant Pharma. Palisade Bio is currently conducting a Phase 1a/b clinical study of PALI-2108, focusing on its safety and tolerability in healthy volunteers and patients with ulcerative colitis. Preliminary data from the Single Ascending Dose stage of the study indicates that PALI-2108 is well-tolerated, with no serious adverse events reported. The drug shows promise with its delayed-release and extended-release characteristics, crucial for targeting ulcerative colitis effectively. The company plans to move forward with Multiple Ascending Dose cohorts to further assess the drug’s safety and pharmacokinetics. Topline data from these studies is expected in the first half of 2025. Palisade Bio has emphasized the importance of regulatory approval and additional funding for the continued development of PALI-2108.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.